Many patients with cancer who could potentially benefit from treatment with chimeric antigen receptor (CAR)-T cells do not have access to this therapy. This Comment explores the unique barriers to a broader clinical adoption of CAR-T cell therapy and propose new routes to improve timely and equitable access to treatment.
